⁍ The group, known as the CoVIg Plasma Alliance, enrolled its first patient in the Phase III trial on Friday.

---

⁍ It aims to enroll 500 adult patients from the United States, Mexico and 16 other countries and hope to have results by the end of the year.

---

– A potentially groundbreaking treatment for a rare blood disorder is now in a late-stage trial, and it’s made from the blood of people who’ve recovered from the disease. “The likelihood it works is very high,” Takeda Pharmaceutical’s CEO tells Reuters. “And that’s why we have launched a campaign in order to accelerate the donation of convalescent plasma to manufacture and produce this product.” The treatment, called hyperimmune globulin, is designed to fight the body’s own immune system against the hepatitis C virus. It’s made from the blood of people who’ve recovered from the disease, known as chronic hepatitis B. The manufacturing process is expensive, but the treatment is convenient because it doesn’t need to be tailored to each patient’s blood type.